



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Lawrence B. Bugaisky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Jeffrey T. Helvey*
Heidi L. Kraus
Edward W. Yee
Albert L. Ferro*
Donald R. Banowitz
Peter A. Jackman
Molly A. McCall
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Albert J. Fasulo II*
Eldora Ellison Floyd
Thomas C. Fiala
Brian J. Del Buono

Virgil Lee Beaston*
Kimberly N. Reddick
Theodore A. Wood
Elizabeth J. Haanes
Bruce E. Chalker
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Uhulier
Rae Lynn Prengaman
Jane Shershenovich*
Lawrence J. Carroll*
George S. Bardmesser
Daniel A. Klein*
Rodney G. Maze
Jason D. Eisenberg
Michael A. Specht
Andrea J. Kamage
Tracy L. Muller

Jon E. Wright*
LuAnne M. Yuricek*

Registered Patent Agents*

Karen R. Markowicz
Nancy J. Leith
Ann E. Summerfield
Helene C. Carlson
Gaby L. Longworth
Matthew J. Dowd
Aaron L. Schwartz
Angelique G. Uy
Boris A. Matvenko
Mary B. Tung
Katrina Y. Pei
Bryan L. Skelton
Robert A. Schwartzman
John J. Figueroa

Timothy A. Doyle
Jennifer R. Mahalingappa
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford
W. Brian Edge

Senior Counsel

Samuel L. Fox
Kenneth C. Bass III
Lisa A. Dunner

*Admitted only in Maryland
*Admitted only in Virginia
*Admitted only in Texas
*Practice Limited to
Federal Agencies

February 25, 2003

WRITER'S DIRECT NUMBER:

(202) 772-8589

INTERNET ADDRESS:

LARRYB@SKGF.COM

Commissioner for Patents
Washington, D.C. 20231

Box: NON-FEE
Art Unit: 1623
Examiner: Lewis, Patrick
Confirmation No.: 3882

Re: U.S. Utility Patent Application
Appl. No. 09/920,286; Filed: August 2, 2001
For: **Process for the Production of Multiple Cross-Linked
Hyaluronic Acid Derivatives**
Inventor: Xiaobin ZHAO
Our Ref: 0623.1110001/LBB/MGP

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Amendment and Reply Under 37 C.F.R. § 1.111; and
2. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

RECEIVED
FEB 27 2003
TECH CENTER 1600/2900

Commissioner for Patents
February 25, 2003
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Lawrence B. Bugaisky
Attorney for Applicant
Registration No. 35,086

LBB/MGP/awt
Enclosures

SKGF_DC1:105484.1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#11/B
3-5-03
[Signature]

In re application of:

Xiaobin ZHAO

Appl. No. 09/920,286

Filed: August 2, 2001

For: **Process for the Production of
Multiple Cross-Linked
Hyaluronic Acid Derivatives**

Confirmation No.: 3882

Art Unit: 1623

Examiner: Lewis, Patrick

Atty. Docket: 0623.1110001/LBB/MGP

Amendment And Reply Under 37 C.F.R. § 1.111

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

FEB 27 2003

TECH CENTER 1600/2900

Sir:

In reply to the Office Action dated **November 25, 2002**, (PTO Prosecution File Wrapper Paper No. 10), Applicant submits the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks and arguments. 37 C.F.R. § 1.121 and MPEP 714; and
- (C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned

under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.